OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free DTCFF Stock Alerts $0.88 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.8850-Day Range$0.88▼$1.4952-Week Range$0.86▼$3.19VolumeN/AAverage Volume571 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Defence Therapeutics alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Defence Therapeutics Stock (OTCMKTS:DTCFF)Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Read More DTCFF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DTCFF Stock News HeadlinesApril 17, 2024 | finance.yahoo.comDefence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline GrowthFebruary 29, 2024 | finanznachrichten.deDefence Therapeutics Inc.: Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing UpdateApril 27, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. January 30, 2024 | finance.yahoo.comDefence Therapeutics Completes 1st Tranche of FinancingJanuary 19, 2024 | finance.yahoo.comDefence FinancingJanuary 13, 2024 | finance.yahoo.comDefence Begins Trading on the OTCQB and Arranges FinancingJanuary 10, 2024 | morningstar.comDefence Therapeutics Inc DTCFFDecember 12, 2023 | finance.yahoo.comRETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)April 27, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. December 11, 2023 | finance.yahoo.comDefence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)November 14, 2023 | finance.yahoo.comDefence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid TumorsNovember 7, 2023 | finance.yahoo.comDefence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine TechnologyOctober 27, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence to Collaborate with Native Ads for Marketing CampaignOctober 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, SwitzerlandOctober 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA VaccinesOctober 25, 2023 | finance.yahoo.comDefence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking PlatformOctober 22, 2023 | investing.comDefence Therapeutics Inc (DTC)October 18, 2023 | finance.yahoo.comDefence's Novel Accutox(TM) Continues to Surprise on Results Against CancerOctober 17, 2023 | theglobeandmail.comBristol Myers Squibb Enters the Multi-Billion-Dollar Oncology RaceOctober 17, 2023 | finance.yahoo.comDefence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid LymphomaOctober 11, 2023 | theglobeandmail.comElli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology RaceOctober 10, 2023 | finance.yahoo.comDefence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer ScienceOctober 6, 2023 | finance.yahoo.comDefence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, SwitzerlandSeptember 28, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence's Innovative Therapeutics Featured on Viewpoint with Dennis QuaidSeptember 25, 2023 | finance.yahoo.comDefence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA VaccinesSeptember 22, 2023 | finance.yahoo.comDefence to Collaborate with Native Ads for Marketing CampaignSeptember 14, 2023 | yahoo.comSelf-defense classes for women hit the mark in North PortSee More Headlines Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:DTCFF CUSIPN/A CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Sebastien Plouffe (Age 52)CEO, President & Director Comp: $81.52kMr. Patrick Joseph Meagher C.A. (Age 38)CPA, CA, CPA, CFO & Director Comp: $57.6kDr. Moutih Rafei Ph.D. (Age 42)Chief Scientific Officer & Director Comp: $9.06kDr. Simon Beaudoin (Age 39)Chief Technical Science Officer Ms. Carrie Cesarone (Age 59)Corporate Secretary Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed in 2024? Defence Therapeutics' stock was trading at $1.65 at the start of the year. Since then, DTCFF shares have decreased by 46.9% and is now trading at $0.8765. View the best growth stocks for 2024 here. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DTCFF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe World's First "$20 Trillion Drug?"Behind the MarketsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
